Celerion acts to meet demand for hospital-based US trials

By Nick Taylor

- Last updated on GMT

Related tags Clinical research Clinical trial

Celerion is partnering to access a medical centre Phase I unit that will support increased demand for trials conducted at US hospitals.

Allying with BryanLGH Health System, a non-profit healthcare organisation, gives Celerion use of 24 in-patient beds in a Lincoln, Nebraska, US hospital. The hospital provides Celerion with on site 24-hour emergency care, which was critical in the Northwick Park incident, and medical expertise.

Hospital-based clinical trial units are common in Europe, Philip Bach, vice president of clinical research at Celerion, told Outsourcing-Pharma, and demand is now increasing in the US.

Increased demand is driven, in part, by US Food and Drug Administration (FDA) pressure for certain types of medicine to be tested in a hospital environment, said Bach. This ensures safety infrastructure needed to handle serious adverse events is on site and operational 24/7.

Celerion and its clients will also benefit from the hospital’s medical expertise and technologies, such as chest X‐rays, PET (positron emission tomography) scans, and MRI (magnetic resonance imaging). These technologies will also support trials at Celerion’s existing Lincoln clinical facility.

Paperwork for the Celerion-BryanLGH Clinical Research Unit has been signed and the partners are now working to implement Celerion’s standard operating practices (SOP). Celerion intends to have this process complete and the site operational by March 2011.

Once operational the unit will perform early stage clinical trials of compounds from all therapeutic areas. The unit will be staffed by BryanLGH and Celerion employees, with the number from each organisation depending on the details of the clinical trial.

Repurposing a site

The hospital unit has been used for patient care for a number of years, Kimberly Russel, president and CEO of BryanLGH, told Outsourcing-Pharma, and is now being repurposed for clinical trials.

Partnering with Celerion expands activities at BryanLGH into clinical research, said Russel, and allows it to support a local company. BryanLGH operates 664-beds that serve patients throughout Nebraska and parts of Kansas, Iowa, South Dakota and other states in the region.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more